Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry

Salvatore Lucio Cutuli; Antonio Artigas; Roberto Fumagalli; Gianpaola Monti; Vito Marco Ranieri; Claudio Ronco; Massimo Antonelli; null The Euphas 2 Collaborative Group; Riccardo Maviglia; Sandra Cicconi; Davide Silvestri; Giuseppe Bello; Alessandra Brendolan; Federico Nalesso; Gianluca Villa; Pasquale Piccinni; Erica Martin; Vincenzo Cantaluppi; Sergio Vesconi; Giampaolo Casella; Egidio Fasanella; Michele Debitonto; Gianmario Monza; Angelo Blasetti; Rosaria Coletta; Michele D’Ambrosio; Gilda Cinnella; Patrizia Murino; Eugenio Piscitelli; Gaetano Centonze; Marco Cucurachi; Giuseppe Altieri; Vincenzo Leonardo; Anna Sara Idra; Goffredo Del Rosso; Maria Polidoro; Nicola Stigliano; Giuseppe Pittella; Gianluca Paternoster; Giuseppe Pulito; Daniela Puscio; Diego Cingolani; Gabriele Falzetti; Pietro Vecchiarelli; Francesco Giunta; Francesco Forfori; Giacomo Castiglione; Stefano Greco; Carlo Capra; Luciano Crema; Leonor Tamayo; Cristina Urbano; Brunello Pezza; Nadia Zarrillo; Pasquale Di Monaco; Giuseppe Climaco; Pasquale De Negri; Pasqualina Modano; Riccardo Pagliarulo; Claudio Petrillo; Tania Stripoli; Roberto Oggioni; Laura Campiglia; Anna Rita Valletta; Manuela Lugano; Domenico Milella; Laura Micucci; Ursula Reist; Rolf Ensner; Christian Gianbarba; Lukas Brander; Rajib Paul; Rajesh Crawla; Sanjeev Jasujia; Rajesh Pande; Pratibha Dileep; Sankaran Sundar; Raju Ganesan; Sandeep Dewan; Vivek Nangia; Raj Kumar Mani; Omender Singh; Pracee Sathe; Gupta Sachin; Pradeep M. D’Costa; Samavedam Srivanas; Yogendra Pal Singh; Kent Doi; Fumika Taki; Ricard Ferrer Roca; Eduardo Romay Medina; Josè Gernacho; Francisco Martí; Alberto Martinez-Ruiz; Fernando Martinez-Sagasti; Rafael Zaragoza Crespo; Paola Torti; Valeria Terzi

doi:10.1186/s13613-016-0178-9

Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry

Salvatore Lucio Cutuli^*, Antonio Artigas, Roberto Fumagalli, Gianpaola Monti, Vito Marco Ranieri, Claudio Ronco, Massimo Antonelli, The Euphas 2 Collaborative Group, Riccardo Maviglia, Sandra Cicconi, Davide Silvestri, Giuseppe Bello, Alessandra Brendolan, Federico Nalesso, Gianluca Villa, Pasquale Piccinni, Erica Martin, Vincenzo Cantaluppi, Sergio Vesconi, Giampaolo CasellaEgidio Fasanella, Michele Debitonto, Gianmario Monza, Angelo Blasetti, Rosaria Coletta, Michele D’Ambrosio, Gilda Cinnella, Patrizia Murino, Eugenio Piscitelli, Gaetano Centonze, Marco Cucurachi, Giuseppe Altieri, Vincenzo Leonardo, Anna Sara Idra, Goffredo Del Rosso, Maria Polidoro, Nicola Stigliano, Giuseppe Pittella, Gianluca Paternoster, Giuseppe Pulito, Daniela Puscio, Diego Cingolani, Gabriele Falzetti, Pietro Vecchiarelli, Francesco Giunta, Francesco Forfori, Giacomo Castiglione, Stefano Greco, Carlo Capra, Luciano Crema, Leonor Tamayo, Cristina Urbano, Brunello Pezza, Nadia Zarrillo, Pasquale Di Monaco, Giuseppe Climaco, Pasquale De Negri, Pasqualina Modano, Riccardo Pagliarulo, Claudio Petrillo, Tania Stripoli, Roberto Oggioni, Laura Campiglia, Anna Rita Valletta, Manuela Lugano, Domenico Milella, Laura Micucci, Ursula Reist, Rolf Ensner, Christian Gianbarba, Lukas Brander, Rajib Paul, Rajesh Crawla, Sanjeev Jasujia, Rajesh Pande, Pratibha Dileep, Sankaran Sundar, Raju Ganesan, Sandeep Dewan, Vivek Nangia, Raj Kumar Mani, Omender Singh, Pracee Sathe, Gupta Sachin, Pradeep M. D’Costa, Samavedam Srivanas, Yogendra Pal Singh, Kent Doi, Fumika Taki, Ricard Ferrer Roca, Eduardo Romay Medina, Josè Gernacho, Francisco Martí, Alberto Martinez-Ruiz, Fernando Martinez-Sagasti, Rafael Zaragoza Crespo, Paola Torti, Valeria Terzi

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

24 Citazioni (Scopus)

Abstract

Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice. Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retrospective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracorporeal endotoxin removal by PMX-HP. Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal (44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % (60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. However, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission. Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal technique.

Lingua originale	English
pagine (da-a)	77-82
Numero di pagine	6
Rivista	Annals of Intensive Care
Volume	6
DOI	https://doi.org/10.1186/s13613-016-0178-9
Stato di pubblicazione	Pubblicato - 2016

Keywords

Critical Care and Intensive Care Medicine
EAA
Extracorporeal endotoxin removal
Infection
Polymyxin-B hemoperfusion
Sepsis
Septic shock

Accesso al documento

10.1186/s13613-016-0178-9

Altri file e collegamenti

Cita questo

Cutuli, S. L., Artigas, A., Fumagalli, R., Monti, G., Ranieri, V. M., Ronco, C., Antonelli, M., The Euphas 2 Collaborative Group, Maviglia, R., Cicconi, S., Silvestri, D., Bello, G., Brendolan, A., Nalesso, F., Villa, G., Piccinni, P., Martin, E., Cantaluppi, V., Vesconi, S., ... Terzi, V. (2016). Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Annals of Intensive Care, 6, 77-82. https://doi.org/10.1186/s13613-016-0178-9

@article{fda55e8f32654589af1230fdef590d1a,

title = "Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry",

abstract = "Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice. Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retrospective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracorporeal endotoxin removal by PMX-HP. Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal (44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % (60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. However, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission. Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal technique.",

keywords = "Critical Care and Intensive Care Medicine, EAA, Extracorporeal endotoxin removal, Infection, Polymyxin-B hemoperfusion, Sepsis, Septic shock, Critical Care and Intensive Care Medicine, EAA, Extracorporeal endotoxin removal, Infection, Polymyxin-B hemoperfusion, Sepsis, Septic shock",

author = "Cutuli, {Salvatore Lucio} and Antonio Artigas and Roberto Fumagalli and Gianpaola Monti and Ranieri, {Vito Marco} and Claudio Ronco and Massimo Antonelli and {The Euphas 2 Collaborative Group} and Riccardo Maviglia and Sandra Cicconi and Davide Silvestri and Giuseppe Bello and Alessandra Brendolan and Federico Nalesso and Gianluca Villa and Pasquale Piccinni and Erica Martin and Vincenzo Cantaluppi and Sergio Vesconi and Giampaolo Casella and Egidio Fasanella and Michele Debitonto and Gianmario Monza and Angelo Blasetti and Rosaria Coletta and Michele D{\textquoteright}Ambrosio and Gilda Cinnella and Patrizia Murino and Eugenio Piscitelli and Gaetano Centonze and Marco Cucurachi and Giuseppe Altieri and Vincenzo Leonardo and Idra, {Anna Sara} and {Del Rosso}, Goffredo and Maria Polidoro and Nicola Stigliano and Giuseppe Pittella and Gianluca Paternoster and Giuseppe Pulito and Daniela Puscio and Diego Cingolani and Gabriele Falzetti and Pietro Vecchiarelli and Francesco Giunta and Francesco Forfori and Giacomo Castiglione and Stefano Greco and Carlo Capra and Luciano Crema and Leonor Tamayo and Cristina Urbano and Brunello Pezza and Nadia Zarrillo and {Di Monaco}, Pasquale and Giuseppe Climaco and {De Negri}, Pasquale and Pasqualina Modano and Riccardo Pagliarulo and Claudio Petrillo and Tania Stripoli and Roberto Oggioni and Laura Campiglia and Valletta, {Anna Rita} and Manuela Lugano and Domenico Milella and Laura Micucci and Ursula Reist and Rolf Ensner and Christian Gianbarba and Lukas Brander and Rajib Paul and Rajesh Crawla and Sanjeev Jasujia and Rajesh Pande and Pratibha Dileep and Sankaran Sundar and Raju Ganesan and Sandeep Dewan and Vivek Nangia and Mani, {Raj Kumar} and Omender Singh and Pracee Sathe and Gupta Sachin and D{\textquoteright}Costa, {Pradeep M.} and Samavedam Srivanas and Singh, {Yogendra Pal} and Kent Doi and Fumika Taki and Roca, {Ricard Ferrer} and Medina, {Eduardo Romay} and Jos{\`e} Gernacho and Francisco Mart{\'i} and Alberto Martinez-Ruiz and Fernando Martinez-Sagasti and Crespo, {Rafael Zaragoza} and Paola Torti and Valeria Terzi",

year = "2016",

doi = "10.1186/s13613-016-0178-9",

language = "English",

volume = "6",

pages = "77--82",

journal = "Annals of Intensive Care",

issn = "2110-5820",

publisher = "Springer-Verlag GmbH and Co. KG",

}

Cutuli, SL, Artigas, A, Fumagalli, R, Monti, G, Ranieri, VM, Ronco, C, Antonelli, M, The Euphas 2 Collaborative Group, Maviglia, R, Cicconi, S, Silvestri, D, Bello, G, Brendolan, A, Nalesso, F, Villa, G, Piccinni, P, Martin, E, Cantaluppi, V, Vesconi, S, Casella, G, Fasanella, E, Debitonto, M, Monza, G, Blasetti, A, Coletta, R, D’Ambrosio, M, Cinnella, G, Murino, P, Piscitelli, E, Centonze, G, Cucurachi, M, Altieri, G, Leonardo, V, Idra, AS, Del Rosso, G, Polidoro, M, Stigliano, N, Pittella, G, Paternoster, G, Pulito, G, Puscio, D, Cingolani, D, Falzetti, G, Vecchiarelli, P, Giunta, F, Forfori, F, Castiglione, G, Greco, S, Capra, C, Crema, L, Tamayo, L, Urbano, C, Pezza, B, Zarrillo, N, Di Monaco, P, Climaco, G, De Negri, P, Modano, P, Pagliarulo, R, Petrillo, C, Stripoli, T, Oggioni, R, Campiglia, L, Valletta, AR, Lugano, M, Milella, D, Micucci, L, Reist, U, Ensner, R, Gianbarba, C, Brander, L, Paul, R, Crawla, R, Jasujia, S, Pande, R, Dileep, P, Sundar, S, Ganesan, R, Dewan, S, Nangia, V, Mani, RK, Singh, O, Sathe, P, Sachin, G, D’Costa, PM, Srivanas, S, Singh, YP, Doi, K, Taki, F, Roca, RF, Medina, ER, Gernacho, J, Martí, F, Martinez-Ruiz, A, Martinez-Sagasti, F, Crespo, RZ, Torti, P & Terzi, V 2016, 'Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry', Annals of Intensive Care, vol. 6, pagg. 77-82. https://doi.org/10.1186/s13613-016-0178-9

TY - JOUR

T1 - Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry

AU - Cutuli, Salvatore Lucio

AU - Artigas, Antonio

AU - Fumagalli, Roberto

AU - Monti, Gianpaola

AU - Ranieri, Vito Marco

AU - Ronco, Claudio

AU - Antonelli, Massimo

AU - The Euphas 2 Collaborative Group, null

AU - Maviglia, Riccardo

AU - Cicconi, Sandra

AU - Silvestri, Davide

AU - Bello, Giuseppe

AU - Brendolan, Alessandra

AU - Nalesso, Federico

AU - Villa, Gianluca

AU - Piccinni, Pasquale

AU - Martin, Erica

AU - Cantaluppi, Vincenzo

AU - Vesconi, Sergio

AU - Casella, Giampaolo

AU - Fasanella, Egidio

AU - Debitonto, Michele

AU - Monza, Gianmario

AU - Blasetti, Angelo

AU - Coletta, Rosaria

AU - D’Ambrosio, Michele

AU - Cinnella, Gilda

AU - Murino, Patrizia

AU - Piscitelli, Eugenio

AU - Centonze, Gaetano

AU - Cucurachi, Marco

AU - Altieri, Giuseppe

AU - Leonardo, Vincenzo

AU - Idra, Anna Sara

AU - Del Rosso, Goffredo

AU - Polidoro, Maria

AU - Stigliano, Nicola

AU - Pittella, Giuseppe

AU - Paternoster, Gianluca

AU - Pulito, Giuseppe

AU - Puscio, Daniela

AU - Cingolani, Diego

AU - Falzetti, Gabriele

AU - Vecchiarelli, Pietro

AU - Giunta, Francesco

AU - Forfori, Francesco

AU - Castiglione, Giacomo

AU - Greco, Stefano

AU - Capra, Carlo

AU - Crema, Luciano

AU - Tamayo, Leonor

AU - Urbano, Cristina

AU - Pezza, Brunello

AU - Zarrillo, Nadia

AU - Di Monaco, Pasquale

AU - Climaco, Giuseppe

AU - De Negri, Pasquale

AU - Modano, Pasqualina

AU - Pagliarulo, Riccardo

AU - Petrillo, Claudio

AU - Stripoli, Tania

AU - Oggioni, Roberto

AU - Campiglia, Laura

AU - Valletta, Anna Rita

AU - Lugano, Manuela

AU - Milella, Domenico

AU - Micucci, Laura

AU - Reist, Ursula

AU - Ensner, Rolf

AU - Gianbarba, Christian

AU - Brander, Lukas

AU - Paul, Rajib

AU - Crawla, Rajesh

AU - Jasujia, Sanjeev

AU - Pande, Rajesh

AU - Dileep, Pratibha

AU - Sundar, Sankaran

AU - Ganesan, Raju

AU - Dewan, Sandeep

AU - Nangia, Vivek

AU - Mani, Raj Kumar

AU - Singh, Omender

AU - Sathe, Pracee

AU - Sachin, Gupta

AU - D’Costa, Pradeep M.

AU - Srivanas, Samavedam

AU - Singh, Yogendra Pal

AU - Doi, Kent

AU - Taki, Fumika

AU - Roca, Ricard Ferrer

AU - Medina, Eduardo Romay

AU - Gernacho, Josè

AU - Martí, Francisco

AU - Martinez-Ruiz, Alberto

AU - Martinez-Sagasti, Fernando

AU - Crespo, Rafael Zaragoza

AU - Torti, Paola

AU - Terzi, Valeria

PY - 2016

Y1 - 2016

N2 - Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice. Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retrospective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracorporeal endotoxin removal by PMX-HP. Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal (44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % (60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. However, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission. Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal technique.

AB - Background: In 2010, the EUPHAS 2 collaborative group created a registry with the purpose of recording data from critically ill patients suffering from severe sepsis and septic shock treated with polymyxin-B hemoperfusion (PMX-HP) for endotoxin removal. The aim of the registry was to verify the application of PMX-HP in the daily clinical practice. Methods: The EUPHAS 2 registry involved 57 centers between January 2010 and December 2014, collecting retrospective data of 357 patients (297 in Europe and 60 in Asia) suffering from severe sepsis and septic shock caused by proved or suspected infection related to Gram negative bacteria. All patients received atleast one cycle of extracorporeal endotoxin removal by PMX-HP. Results: Septic shock was diagnosed in 305 (85.4 %) patients. The most common source of infection was abdominal (44.0 %) followed by pulmonary (17.6 %). Gram negative bacteria represented 60.6 % of the pathogens responsible of infection. After 72 h from the first cycle of PMX-HP, some of the SOFA score components significantly improved with respect to baseline: cardiovascular (2.16 ± 1.77 from 3.32 ± 1.29, p < 0.0001), respiratory (1.95 ± 0.95 from 2.40 ± 1.06, p < 0.001) and renal (1.84 ± 1.77 from 2.23 ± 1.62, p = 0.013). Overall 28-day survival rate was 54.5 % (60.4 % in abdominal and 47.5 % in pulmonary infection). Patients with abdominal infection treated with PMX-HP within 24 h from the diagnosis of septic shock had a 28-day survival rate of 64.5 %. Patients showing a significantly cardiovascular improvement after PMX-HP had a 28-survival rate of 75 % in comparison to the 39 % of patients who did not (p < 0.001). Cox regression analysis found the variation of cardiovascular, respiratory and coagulation SOFA to be independent covariates for 28-day survival. In European patients were observed a higher 28-day (58.8 vs. 34.5 %, p = 0.003), ICU (59 vs. 36.7 %, p = 0.006) and hospital survival rate (53.2 vs. 35 %, p = 0.02) than in Asian patients. However, the two populations were highly heterogeneous in terms of source of infection and severity scores at admission. Conclusion: The EUPHAS 2 is the largest registry conducted outside Japan on the clinical use of PMX-HP in septic patients. Data analysis confirmed the feasibility of PMX-HP to treat septic patients in daily clinical practice, showing clinical benefits associated with endotoxin removal without significant adverse events related to the extracorporeal technique.

KW - Critical Care and Intensive Care Medicine

KW - EAA

KW - Extracorporeal endotoxin removal

KW - Infection

KW - Polymyxin-B hemoperfusion

KW - Sepsis

KW - Septic shock

KW - Critical Care and Intensive Care Medicine

KW - EAA

KW - Extracorporeal endotoxin removal

KW - Infection

KW - Polymyxin-B hemoperfusion

KW - Sepsis

KW - Septic shock

UR - http://hdl.handle.net/10807/92798

UR - http://www.annalsofintensivecare.com/

U2 - 10.1186/s13613-016-0178-9

DO - 10.1186/s13613-016-0178-9

M3 - Article

SN - 2110-5820

VL - 6

SP - 77

EP - 82

JO - Annals of Intensive Care

JF - Annals of Intensive Care

ER -

Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo